Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma

Alpha-9 Oncology, Inc. announced that the first participant has been dosed in the Phase I study evaluating 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor for the imaging of locally advanced or metastatic melanoma.